Evidence mapPaperPMID 40906176Full record

ReviewBiology2025

Managing Spinal Muscular Atrophy: A Look at the Biology and Treatment Strategies.

Arianna Vezzoli, Daniele Bottai, Raffaella Adami

Abstract readReview
In one paragraph

Review in Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Arianna VezzoliDepartment of Pharmacological Science, University of Milan, Via G. Balzaretti 9, 20133 Milan, Italy.ORCID 0009-0001-8693-6330
Daniele BottaiDepartment of Pharmacological Science, University of Milan, Via G. Balzaretti 9, 20133 Milan, Italy.ORCID 0000-0002-7951-9512
Raffaella AdamiDepartment of Pharmacological Science, University of Milan, Via G. Balzaretti 9, 20133 Milan, Italy.ORCID 0000-0001-9656-3219

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since its discovery in the late 19th century, spinal muscular atrophy (SMA) has had a significant medical and societal impact, primarily affecting newborns, toddlers, and young adults. While new pharmaceutical strategies are effective in treating SMA in a particular subset of patients, continued research is necessary to improve the well-being of patients. Treatments are needed for those who do not respond to newly approved drugs and older patients with significantly compromised neuron systems. After summarizing SMA genotypes, phenotypes, and approved pharmacological treatments, this review presents ongoing trials for approved and new molecules, new formulations, and administration methods. Based on the work of our lab, we also discuss nutritional interventions that aim to counteract the oxidative stress present in SMA cells. Finally, we assess rehabilitative interventions, focusing on psychological approaches.

Indexed as

curcuminonasemnogene abeparvovecplastin 3psychological supportrehabilitationrisdiplamspinal muscle atrophyspinrazasurvival motor neuron

Identifiers

PMID40906176
PMCPMC12384012

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.